Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB.
Social Sciences Lead, The Office of Lifelong Learning and the Physician Learning Program, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB.
Healthc Policy. 2020 Feb;15(3):16-27. doi: 10.12927/hcpol.2020.26133.
Although biosimilars offer cost savings in Canadian healthcare, uptake is low. We discuss the literature on international experiences with biosimilar adoption in the context of the Diffusion of Innovations model. We highlight potential challenges with biosimilar implementation and gaps in research needed to inform implementation efforts. We observe a lack of systematic description of implementation design and evaluation and a paucity of in-depth and engaged research to understand stakeholders' pragmatic considerations and the knowledge, messages and meanings that shape clinician and patient decisions to choose biosimilars.
尽管生物类似药为加拿大的医疗保健带来了成本节约，但采用率却很低。我们在创新扩散模型的背景下讨论了国际上生物类似药采用经验的文献。我们强调了生物类似药实施中潜在的挑战以及为实施工作提供信息所需的研究空白。我们观察到缺乏对实施设计和评估的系统描述，以及缺乏深入和参与性的研究来了解利益相关者的实际考虑因素以及塑造临床医生和患者选择生物类似药的决策的知识、信息和意义。
